Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada
Supernus Pharmaceuticals, Inc. (SUPN)
Last supernus pharmaceuticals, inc. earnings: 2/25 04:40 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.supernus.com
Company Research
Source: Business Wire
Postpartum depression (PPD) affects up to one in five Canadian women1; it is the most common complication2 related to childbearing and a leading cause of maternal death in Canada3Left untreated, PPD can have short- and long-term consequences on maternal health, child development and family well-being4,5,6ZURZUVAE is a 14-day, oral single course of treatment that offers relief from depressive symptoms as early as Day 3, a significant step forward from the current standards of PPD care TORONTO--(BUSINESS WIRE)--Biogen Canada Inc. today announced that Health Canada has issued a Notice of Compliance (NOC) for ZURZUVAE™ (zuranolone) for the treatment of moderate or severe postpartum depression (PPD) in adults following childbirth. ZURZUVAE is a once-daily, 14-day oral single course treatment for women with PPD. This first-of-its-kind treatment offers relief from depressive symptoms, with benefits seen in clinical studies as early as day 3, significant reduction of symptoms by the end of
Show less
Read more
Impact Snapshot
Event Time:
SUPN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SUPN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SUPN alerts
High impacting Supernus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SUPN
News
- Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference [Yahoo! Finance]Yahoo! Finance
- Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual ConferenceGlobeNewswire
- Supernus Pharmaceuticals (NASDAQ:SUPN) had its "sell (d+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Assessing Supernus Pharmaceuticals After FDA Pipeline News and 24% Jump in 2025 [Yahoo! Finance]Yahoo! Finance
SUPN
Earnings
- 11/4/25 - Miss
SUPN
Sec Filings
- 11/24/25 - Form 4
- 11/17/25 - Form 4
- 11/14/25 - Form SCHEDULE
- SUPN's page on the SEC website